Angeion begins European trials of Sentinel 2010:
This article was originally published in Clinica
Angeion has begun clinical evaluation of its Sentinel 2010 implantable cardioverter defibrillator. The first device was implanted in a patient in the Czech Republic. The 60 cc 2010 series weighs 110 g and stores 5.5 minutes of ECG. It is based on the Sentinel 2000, which is currently in US clinical trials and has been audited for CE marking by TUV Product Services of Munich, Germany.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.